HALO
Halozyme Therapeutics, Inc. · Healthcare
Insiders sold $37.8M of Halozyme Therapeutics, Inc. in the last 12 months and bought none
HALO over the last year
HALO after insider buys
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Congress
Members reported 5 trades in HALO since 2023.
Every filing
111 insider filings since 2018, newest first
Michael J. Labarre · SVP and Chief Technical Officer
Michael J. Labarre · SVP and Chief Technical Officer
Helen Torley · President and CEO
Jeffrey William Henderson · Director
Michael J. Labarre · SVP and Chief Technical Officer
Helen Torley · President and CEO
Michael J. Labarre · SVP and Chief Technical Officer
Nicole Labrosse · SVP and CFO
Michael J. Labarre · SVP and Chief Technical Officer
Helen Torley · President and CEO
Helen Torley · President and CEO
Michael J. Labarre · SVP and Chief Technical Officer
Helen Torley · President and CEO
Michael J. Labarre · SVP and Chief Technical Officer
Matthew L. Posard · Director
Helen Torley · President and CEO
Nicole Labrosse · SVP and CFO
Michael J. Labarre · SVP and Chief Technical Officer
Helen Torley · President and CEO
Connie Matsui · Director
Helen Torley · President and CEO
Michael J. Labarre · SVP and Chief Technical Officer
Helen Torley · President and CEO
Jean-Pierre Bizzari · Director
Helen Torley · President and CEO
Helen Torley · President and CEO
Michael J. Labarre · SVP and Chief Technical Officer
Helen Torley · President and CEO
Helen Torley · President and CEO
Kenneth J Kelley · Director
Helen Torley · President and CEO
Michael J. Labarre · SVP and Chief Technical Officer
Helen Torley · President and CEO
Kenneth J Kelley · Director
Michael J. Labarre · SVP and Chief Technical Officer
Helen Torley · President and CEO
Kenneth J Kelley · Director
Kenneth J Kelley · Director
Michael J. Labarre · SVP and Chief Technical Officer
Kenneth J Kelley · Director
Kenneth J Kelley · Director
Kenneth J Kelley · Director
Jeffrey William Henderson · Director
James M Daly · Director
Helen Torley · President and CEO
Michael J. Labarre · SVP and Chief Technical Officer
Michael J. Labarre · SVP and Chief Technical Officer
Michael J. Labarre · SVP and Chief Technical Officer
Connie Matsui · Director
Michael J. Labarre · SVP and Chief Technical Officer
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.